Rona Yaeger

Active 2008–2025

152
Papers
35,105
Citations
74
h-index
142
i10-index

Citations

Citations per year for Rona Yaeger1976: 1 citations1977: 1 citations1992: 2 citations1996: 1 citations1998: 2 citations2001: 1 citations2004: 1 citations2007: 1 citations2009: 3 citations2010: 2 citations2011: 1 citations2012: 12 citations2013: 44 citations2014: 59 citations2015: 96 citations2016: 97 citations2017: 174 citations2018: 288 citations2019: 1,217 citations2020: 1,919 citations2021: 2,090 citations2022: 1,888 citations2023: 1,736 citations2024: 2,722 citations2025: 1,536 citations2026: 64 citations1978–1991: no citations, so these years are not shown1993–1995: no citations, so these years are not shown1997: no citations, so this year is not shown1999–2000: no citations, so these years are not shown2002–2003: no citations, so these years are not shown2005–2006: no citations, so these years are not shown2008: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,587 citing papers, 27% of this breakdownChina: 2,448 citing papers, 14.4% of this breakdownItaly: 992 citing papers, 5.8% of this breakdownUnited Kingdom: 898 citing papers, 5.3% of this breakdownGermany: 826 citing papers, 4.9% of this breakdownFrance: 616 citing papers, 3.6% of this breakdownSpain: 603 citing papers, 3.5% of this breakdownJapan: 583 citing papers, 3.4% of this breakdownNetherlands: 532 citing papers, 3.1% of this breakdownCanada: 451 citing papers, 2.6% of this breakdownAustralia: 389 citing papers, 2.3% of this breakdownSwitzerland: 354 citing papers, 2.1% of this breakdown
0%27%Other 22%

Fields

  • Medicine59.9%
  • Biochemistry, Genetics and Molecular Biology34.5%
  • Immunology and Microbiology2.5%
  • Computer Science1.1%
  • Engineering0.6%
  • Neuroscience0.2%
  • Other1.2%

Topics

  • Cancer Genomics and Diagnostics9.1%
  • Cancer Immunotherapy and Biomarkers6.7%
  • Colorectal Cancer Treatments and Studies5%
  • Genetic factors in colorectal cancer4.6%
  • Lung Cancer Treatments and Mutations3.7%
  • Melanoma and MAPK Pathways2.5%
  • Other68.4%

Coauthors

All papers

Open in search
  1. Tumor mutational load predicts survival after immunotherapy across multiple cancer types

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philip H. Gutin, Cameron Brennan, Viviane Tabar, Ingo K. Mellinghoff, Lisa M. DeAngelis, Charlotte E. Ariyan, Nancy Y. Lee, William D. Tap, Mrinal M. Gounder, Sandra P. D’Angelo, Leonard B. Saltz, Zsofia K. Stadler, Howard I. Scher, José Baselga, Pedram Razavi, Christopher A. Klebanoff, Rona Yaeger, Neil H. Segal, Geoffrey Y. Ku, Ronald P. DeMatteo, Marc Ladanyi, Naiyer A. Rizvi, Michael F. Berger, Nadeem Riaz, David B. Solit, Timothy A. Chan, Luc G.T. Morris - Nature Genetics 2019 cited by 4,358

  2. OncoKB: A Precision Oncology Knowledge Base

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Antonio Omuro, Michael A. Postow, Dana E. Rathkopf, Alexander N. Shoushtari, Neerav Shukla, Martin H. Voss, Ederlinda Paraiso, Ahmet Zehir, Michael F. Berger, Barry S. Taylor, Leonard B. Saltz, Gregory J. Riely, Marc Ladanyi, David M. Hyman, José Baselga, Paul Sabbatini, David B. Solit, Nikolaus Schultz - JCO Precision Oncology 2017 cited by 2,698

  3. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kurt A. Schalper, Luis A. Díaz - New England Journal of Medicine 2022 cited by 1,542

  4. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Laetitia Borsu, Justyna Sadowska, Jacklyn Casanova, Ruben Bacares, Iwona Kiecka, Anna Razumova, Julie B Son, Lisa Stewart, Tessara Baldi, Kerry Mullaney, Hikmat Al‐Ahmadie, Efsevia Vakiani, Adam Abeshouse, Alexander Penson, Philip Jonsson, Niedzica Camacho, Matthew T. Chang, Helen Won, Benjamin Groß, Ritika Kundra, Zachary Heins, Hsiao‐Wei Chen, Sarah Phillips, Hongxin Zhang, Jiaojiao Wang, Angelica Ochoa, Jonathan Wills, Michael Eubank, Stacy B. Thomas, Stuart M. Gardos, Dalicia N. Reales, Jesse Galle, Robert Durany, Roy Cambria, Wassim Abida, Andrea Cercek, Darren R. Feldman, Mrinal M. Gounder, A. Ari Hakimi, James J. Harding, Gopa Iyer, Yelena Y. Janjigian, Emmet Jordan, Ciara M. Kelly, Maeve A. Lowery, Luc G.T. Morris, Antonio Omuro, Nitya Raj, Pedram Razavi, Alexander N. Shoushtari, Neerav Shukla, Tara E. Soumerai, Anna M. Varghese, Rona Yaeger, Jonathan Coleman, Bernard H. Bochner, Gregory J. Riely, Leonard B. Saltz, Howard I. Scher, Paul Sabbatini, Mark E. Robson, David S. Klimstra, Barry S. Taylor, José Baselga, Nikolaus Schultz, David M. Hyman, Maria E. Arcila, David B. Solit, Marc Ladanyi, Michael F. Berger - Nature Medicine 2017 cited by 3,517

  5. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael D. Pickard, Janna Christy‐Bittel, Lisa Anderson, Victor Sandor, Josep Tabernero - New England Journal of Medicine 2019 cited by 1,465

  6. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yelena Y. Janjigian, Michael J. Morris, Robert J. Motzer, Eileen M. O’Reilly, Michael A. Postow, Nitya Raj, Gregory J. Riely, Mark E. Robson, Jonathan E. Rosenberg, Anton Safonov, Alexander N. Shoushtari, William D. Tap, Min Yuen Teo, Anna M. Varghese, Martin H. Voss, Rona Yaeger, Marjorie G. Zauderer, Nadeem R. Abu‐Rustum, Julio García‐Aguilar, Bernard H. Bochner, A. Ari Hakimi, William R. Jarnagin, David R. Jones, Daniela Molena, Luc G.T. Morris, Eric Rios‐Doria, Paul Russo, Samuel Singer, Vivian E. Strong, Debyani Chakravarty, Lora H. Ellenson, Anuradha Gopalan, Jorge S. Reis‐Filho, Britta Weigelt, Marc Ladanyi, Mithat Gönen, Sohrab P. Shah, Joan Massagué, Jianjiong Gao, Ahmet Zehir, Michael F. Berger, David B. Solit, Samuel F. Bakhoum, Francisco Sánchez-Vega, Nikolaus Schultz - Cell 2022 cited by 663

  7. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C

    Authors: , , , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 485

  8. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , José G. Guillem, Larissa K. Temple, Iris H. Wei, Maria Widmar, Sabrina T. Lin, Neil H. Segal, Andrea Cercek, Rona Yaeger, J. Joshua Smith, Karyn A. Goodman, Abraham J. Wu, Leonard B. Saltz - Journal of Clinical Oncology 2022 cited by 906

  9. Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 468

  10. Adagrasib in Advanced Solid Tumors Harboring aKRASG12CMutation

    Authors: , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 276

  11. EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2020 cited by 488

  12. Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 cited by 544

  13. Chromothripsis drives the evolution of gene amplification in cancer

    Authors: , , , , , , , , , , , , , , - Nature 2020 cited by 474

  14. A rectal cancer organoid platform to study individual responses to chemoradiation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Iva Petkovska, Andrea Cercek, Katia Manova‐Todorova, Leonard B. Saltz, Jessica A. Lavery, Ronald P. DeMatteo, Joan Massagué, Philip B. Paty, Rona Yaeger, Xi Chen, Sujata Patil, Hans Clevers, Michael F. Berger, Scott W. Lowe, Jinru Shia, Paul B. Romesser, Lukas E. Dow, Julio García‐Aguilar, Charles L. Sawyers, J. Joshua Smith - Nature Medicine 2019 cited by 568

  15. Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2018 cited by 864

  16. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2012 cited by 1,914

  17. Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Andrea Cercek, Rona Yaeger, Garrett M. Nash, Maria Widmar, Iris H. Wei, Emmanouil P. Pappou, Martin R. Weiser, Philip B. Paty, J. Joshua Smith, Abraham J. Wu, Marc J. Gollub, Leonard B. Saltz, Julio García‐Aguilar - Journal of Clinical Oncology 2023 cited by 321

  18. Assessment of a Watch-and-Wait Strategy for Rectal Cancer in Patients With a Complete Response After Neoadjuvant Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2019 cited by 594

  19. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martin R. Weiser, Julio García Aguilar, David S. Klimstra, Luis A. Díaz, José Baselga, Liying Zhang, Marc Ladanyi, David M. Hyman, David B. Solit, Mark E. Robson, Barry S. Taylor, Kenneth Offit, Michael F. Berger, Zsofia K. Stadler - Journal of Clinical Oncology 2018 cited by 627

  20. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2018 cited by 583

  21. Targeting Alterations in the RAF–MEK Pathway

    Authors: , - Cancer Discovery 2019 cited by 484

  22. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2018 cited by 645

  23. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS

    Authors: , , , , , , , , , , , , , , , , , , - Nature 2017 cited by 562

  24. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robin Kate Kelley, Alberto Bardelli, A. John Iafrate, William C. Hahn, Cyril H. Benes, David T. Ting, Hiroshi Hirai, Gad Getz, Dejan Juric, Andrew X. Zhu, Ryan B. Corcoran, Nabeel Bardeesy - Cancer Discovery 2019 cited by 371